AU1703799A - Cyclooxygenase-2 inhibition - Google Patents

Cyclooxygenase-2 inhibition

Info

Publication number
AU1703799A
AU1703799A AU17037/99A AU1703799A AU1703799A AU 1703799 A AU1703799 A AU 1703799A AU 17037/99 A AU17037/99 A AU 17037/99A AU 1703799 A AU1703799 A AU 1703799A AU 1703799 A AU1703799 A AU 1703799A
Authority
AU
Australia
Prior art keywords
cyclooxygenase
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17037/99A
Inventor
Andrew J. Dannenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of AU1703799A publication Critical patent/AU1703799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU17037/99A 1997-12-17 1998-12-07 Cyclooxygenase-2 inhibition Abandoned AU1703799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6995597P 1997-12-17 1997-12-17
US60069955 1997-12-17
PCT/US1998/025206 WO1999030721A1 (en) 1997-12-17 1998-12-07 Cyclooxygenase-2 inhibition

Publications (1)

Publication Number Publication Date
AU1703799A true AU1703799A (en) 1999-07-05

Family

ID=22092236

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17037/99A Abandoned AU1703799A (en) 1997-12-17 1998-12-07 Cyclooxygenase-2 inhibition

Country Status (4)

Country Link
EP (1) EP1039914A4 (en)
AU (1) AU1703799A (en)
CA (1) CA2313049A1 (en)
WO (1) WO1999030721A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357525A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of her-2/neu
EP1064940A1 (en) * 1999-07-02 2001-01-03 Universitair Medisch Centrum Utrecht Antiviral therapy
EP1194141B1 (en) * 1999-07-02 2005-08-17 Universitair Medisch Centrum Utrecht Antiviral therapy
US6787573B2 (en) 1999-07-02 2004-09-07 Universiteit Utrecht Antiviral therapy
CA2403358A1 (en) * 2000-03-17 2001-09-20 Universiteit Utrecht Antiviral therapy
CA2472459A1 (en) * 2002-01-10 2003-07-24 Kong Teck Chong Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections
CN104023726A (en) 2011-10-21 2014-09-03 艾伯维公司 Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
JP7129703B2 (en) 2016-04-28 2022-09-02 エモリー ユニバーシティー Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996039144A1 (en) * 1995-06-06 1996-12-12 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
CA2246265A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
CA2246356A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist

Also Published As

Publication number Publication date
EP1039914A1 (en) 2000-10-04
EP1039914A4 (en) 2007-06-27
CA2313049A1 (en) 1999-06-24
WO1999030721A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
AU1709299A (en) Mixer-injectors
AU8921698A (en) Follistatin-3
AU9414098A (en) Ascorbyl-phosphoryl-cholesterol
AU6598798A (en) Resorcinyl-triazines
AU1027499A (en) 32P-polyphosphazene
AU9513298A (en) Fluoranthenopyrans
AU5272198A (en) EMP-charge-eliminator
AU7476598A (en) 18-substituted-19-nor-vitamin d compounds
AU1703799A (en) Cyclooxygenase-2 inhibition
AU4117497A (en) Micropolarimeter
AU6998698A (en) Dioxacycloalkan-8-one
AU6185898A (en) Clavaspirins
AU7761998A (en) Korrosionsschutzanstrichstoff
AU8214598A (en) 3-benzylpiperidine
AU6508298A (en) Fouling inhibition
AU3953899A (en) Cyclooxygenase-2 inhibitors
AU8991998A (en) Renovative pipeliner
AU5391798A (en) Thiamacrolides
AU4469997A (en) Heregulin-gamma
AU9183798A (en) Catamaran - bicycle - kayak
AU5540298A (en) Rockbolts
AU8121298A (en) G-seat
AU7780498A (en) Cafetiere
AU6507298A (en) Renovative pipeliner
AU6237398A (en) N-het-substituted glycerophosphoethanolamines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase